Physician profile
Ching Wang
NPI 1881795052
$6,657.53
in general payments reported to CMS, 2019-2025
32 companies · $941 in 2025
The $941 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $1,079 · 2021: $1,456 · 2022: $1,441 · 2023: $113 · 2024: $1,441 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,476 · Education: $19.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,475.79 |
| Education | $19.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,907.77 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $583.36 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Nestle Healthcare Nutrition INC. | $436.36 | 2021-2023 | |
| Gilead Sciences, INC. | $384.79 | 2019-2025 | Stribild |
| Daiichi Sankyo INC. | $362.30 | 2020-2025 | Injectafer |
| Merck Sharp & Dohme LLC | $314.44 | 2019-2024 | Dificid |
| Janssen Biotech, INC. | $296.19 | 2020-2024 | Stelara, Tremfya |
| Pfizer INC. | $249.79 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $229.24 | 2024-2025 | Iqirvo, Bylvay |
| E.R. Squibb & Sons, L.L.C. | $206.75 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.23 | 2020-2024 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $172.49 | 2025 | Terlivaz |
| Aimmune Therapeutics, INC. | $170.15 | 2024-2025 | Vowst, Zenpep |
| Qol Medical, LLC | $162.80 | 2020-2021 | |
| Lilly USA, LLC | $132.84 | 2024 | Omvoh |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $103.14 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $98.39 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $96.44 | 2020 | |
| Intercept Pharmaceuticals, INC. | $94.05 | 2019-2022 | |
| Celgene Corporation | $67.48 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $62.59 | 2020-2021 | |
| Ardelyx, INC. | $52.63 | 2025 | Ibsrela |
| Redhill Biopharma INC. | $44.35 | 2020-2021 | |
| Madrigal Pharmaceuticals | $43.44 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $35.29 | 2024 | Dupixent |
| Intuitive Surgical, INC. | $34.59 | 2020 | |
| Lucid Diagnostics INC. | $32.92 | 2022 | |
| Pharmacosmos Therapeutics INC. | $17.93 | 2022 | |
| Eisai INC. | $17.66 | 2021 | |
| Amag Pharmaceuticals, INC. | $15.13 | 2021 | |
| Shionogi INC | $13.50 | 2019 | |
| Genzyme Corporation | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ching Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.